Leao J C, Frezzini C, Porter S
Departamento de Clinica e Odontologia Preventiva, Universidade Federal de Pernambuco, Recife, PE, Brazil.
Oral Dis. 2004 Nov;10(6):327-9. doi: 10.1111/j.1601-0825.2004.01042.x.
Enfuvirtide is the first of a new class of antiretroviral agents recently approved for the treatment of human immunodeficiency virus (HIV)-1 infection. Present available data suggest that enfuvirtide may be a promising agent for the control of HIV infection in patients who have previously received reverse transcriptase inhibitor and protease inhibitor regimens and who are either intolerant to such drugs and/or who have gone into virological failure. Perhaps the greater limitation to the clinical use of enfuvirtide is the cost, limiting its use in the developing world.
恩夫韦肽是最近被批准用于治疗人类免疫缺陷病毒（HIV）-1感染的一类新型抗逆转录病毒药物中的首个药物。目前可得的数据表明，对于先前接受过逆转录酶抑制剂和蛋白酶抑制剂治疗方案、对这类药物不耐受和/或出现病毒学失败的患者，恩夫韦肽可能是控制HIV感染的一种有前景的药物。或许限制恩夫韦肽临床应用的更大因素是成本，这限制了它在发展中世界的使用。
